[go: up one dir, main page]

NO20022633D0 - 4-Pyrimidinyl-N-acyl-L-fenylalaniner - Google Patents

4-Pyrimidinyl-N-acyl-L-fenylalaniner

Info

Publication number
NO20022633D0
NO20022633D0 NO20022633A NO20022633A NO20022633D0 NO 20022633 D0 NO20022633 D0 NO 20022633D0 NO 20022633 A NO20022633 A NO 20022633A NO 20022633 A NO20022633 A NO 20022633A NO 20022633 D0 NO20022633 D0 NO 20022633D0
Authority
NO
Norway
Prior art keywords
pyrimidinyl
phenylalanine
acyl
Prior art date
Application number
NO20022633A
Other languages
English (en)
Other versions
NO20022633L (no
NO322866B1 (no
Inventor
Achyutharao Sidduri
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20022633L publication Critical patent/NO20022633L/no
Publication of NO20022633D0 publication Critical patent/NO20022633D0/no
Publication of NO322866B1 publication Critical patent/NO322866B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20022633A 1999-12-06 2002-06-04 4-Pyrimidinyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter og for behandling av sykdom, farmasoytiske preparater inneholdende slike, fremgangsmate for fremstilling av farmasoytisk preparat inneholdende disse og anvendelse av disse for fremstilling av medikament for behandling av sykdommer. NO322866B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16908999P 1999-12-06 1999-12-06
PCT/EP2000/011884 WO2001042225A2 (en) 1999-12-06 2000-11-28 4-pyrimidinyl-n-acyl-l-phenylalanines

Publications (3)

Publication Number Publication Date
NO20022633L NO20022633L (no) 2002-06-04
NO20022633D0 true NO20022633D0 (no) 2002-06-04
NO322866B1 NO322866B1 (no) 2006-12-18

Family

ID=22614222

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022633A NO322866B1 (no) 1999-12-06 2002-06-04 4-Pyrimidinyl-N-acyl-L-fenylalaniner, anvendelse av disse som medikamenter og for behandling av sykdom, farmasoytiske preparater inneholdende slike, fremgangsmate for fremstilling av farmasoytisk preparat inneholdende disse og anvendelse av disse for fremstilling av medikament for behandling av sykdommer.

Country Status (35)

Country Link
EP (1) EP1237878B1 (no)
JP (1) JP3824935B2 (no)
KR (1) KR100522344B1 (no)
CN (1) CN1218943C (no)
AR (1) AR034401A1 (no)
AT (1) ATE357433T1 (no)
AU (1) AU783348B2 (no)
BR (1) BR0016195A (no)
CA (1) CA2392570C (no)
CO (1) CO5080772A1 (no)
CY (1) CY1106626T1 (no)
CZ (1) CZ303435B6 (no)
DE (1) DE60034061T2 (no)
DK (1) DK1237878T3 (no)
EG (1) EG24361A (no)
ES (1) ES2282162T3 (no)
HK (1) HK1054384B (no)
HR (1) HRP20020468B1 (no)
HU (1) HU229105B1 (no)
IL (2) IL149617A0 (no)
JO (1) JO2283B1 (no)
MA (1) MA26850A1 (no)
MX (1) MXPA02005564A (no)
MY (1) MY126972A (no)
NO (1) NO322866B1 (no)
NZ (1) NZ518828A (no)
PE (1) PE20010961A1 (no)
PL (1) PL207160B1 (no)
PT (1) PT1237878E (no)
RS (1) RS50371B (no)
RU (1) RU2266901C2 (no)
SI (1) SI1237878T1 (no)
TW (1) TWI256387B (no)
WO (1) WO2001042225A2 (no)
ZA (1) ZA200203533B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
AU7874001A (en) * 2000-08-18 2002-03-04 Ajinomoto Kk Novel phenylalanine derivatives
AR033765A1 (es) * 2001-05-22 2004-01-07 Syngenta Participations Ag Procedimiento para la preparacion de derivados 3-alquil-3h-isobenzofuran-1-ona 7-sustituidos.
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
CA2576647C (en) * 2004-08-16 2011-12-13 Merck & Co., Inc. Vla-4 antagonists
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
US20090137601A1 (en) * 2005-11-23 2009-05-28 Astrazeneca Ab L-Phenylalanine Derivatives
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007091046A1 (en) * 2006-02-09 2007-08-16 Astrazeneca Ab Chemical compounds
US7879837B2 (en) 2006-06-19 2011-02-01 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
EP2222646B1 (en) 2007-09-17 2014-01-22 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
DK2203431T3 (da) 2007-09-17 2011-11-21 Abbott Lab Antiinfektiøse pyrimidiner og anvendelser heraf
CA2699989C (en) 2007-09-17 2014-03-25 Abbott Laboratories N-phenyl-dioxo-hydro pyrimidines useful as hepatitis c virus (hcv) inhibitor
US8299149B2 (en) * 2008-12-22 2012-10-30 Icl-Ip America Inc. Water miscible solvent based process for purifying a bisphosphate
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
UA113498C2 (xx) 2010-07-16 2017-02-10 Фосфінові ліганди для каталітичних реакцій
SG10201505540SA (en) 2010-07-16 2015-08-28 Abbott Lab Process for preparing antiviral compounds
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
KR20140127234A (ko) * 2012-01-27 2014-11-03 에프. 호프만-라 로슈 아게 Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
MX373389B (es) * 2013-10-29 2020-05-12 Ea Pharma Co Ltd Derivado de sulfonamida y uso farmaceutico del mismo.
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH516578A (de) * 1967-11-02 1971-12-15 Bayer Ag Verfahren zur Herstellung von heterocyclische Acylaminogruppen enthaltenden Arylsulfonylharnstoffen mit blutdrucksenkender Wirkung
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
AU726585B2 (en) * 1997-05-29 2000-11-09 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
JP3727536B2 (ja) * 1997-08-22 2005-12-14 エフ．ホフマン−ラ ロシュ アーゲー Ｎ−アルカノイルフェニルアラニン誘導体
DK1005445T3 (da) * 1997-08-22 2004-10-04 Hoffmann La Roche N-alkanoylphenylaninderivater
CN1231212C (zh) * 1999-01-22 2005-12-14 依兰制药公司 抑制vla－4介导的白细胞粘着的多环化合物

Also Published As

Publication number Publication date
RU2266901C2 (ru) 2005-12-27
EP1237878B1 (en) 2007-03-21
CZ303435B6 (cs) 2012-09-12
CO5080772A1 (es) 2001-09-25
CY1106626T1 (el) 2012-01-25
NO20022633L (no) 2002-06-04
ZA200203533B (en) 2003-08-04
AU783348B2 (en) 2005-10-20
NO322866B1 (no) 2006-12-18
HUP0204081A2 (en) 2003-05-28
HRP20020468A2 (en) 2004-04-30
HK1054384B (zh) 2005-12-09
IL149617A (en) 2007-10-31
PE20010961A1 (es) 2001-09-26
CN1407972A (zh) 2003-04-02
WO2001042225A2 (en) 2001-06-14
CA2392570C (en) 2010-05-11
JP2003516396A (ja) 2003-05-13
RU2002117422A (ru) 2004-03-10
ES2282162T3 (es) 2007-10-16
HU229105B1 (en) 2013-07-29
CZ20022351A3 (cs) 2003-04-16
EP1237878A2 (en) 2002-09-11
CA2392570A1 (en) 2001-06-14
AR034401A1 (es) 2004-02-25
HUP0204081A3 (en) 2003-07-28
KR100522344B1 (ko) 2005-10-20
AU2669601A (en) 2001-06-18
WO2001042225A8 (en) 2002-06-06
YU40402A (sh) 2005-03-15
PL207160B1 (pl) 2010-11-30
DK1237878T3 (da) 2007-07-30
WO2001042225A3 (en) 2002-02-21
MY126972A (en) 2006-11-30
JO2283B1 (en) 2005-09-12
DE60034061D1 (de) 2007-05-03
IL149617A0 (en) 2002-11-10
MXPA02005564A (es) 2002-09-02
JP3824935B2 (ja) 2006-09-20
EG24361A (en) 2009-03-04
HRP20020468B1 (en) 2009-02-28
BR0016195A (pt) 2002-08-13
MA26850A1 (fr) 2004-12-20
RS50371B (sr) 2009-11-10
PT1237878E (pt) 2007-06-18
HK1054384A1 (en) 2003-11-28
SI1237878T1 (sl) 2007-08-31
TWI256387B (en) 2006-06-11
KR20020063906A (ko) 2002-08-05
DE60034061T2 (de) 2007-12-13
ATE357433T1 (de) 2007-04-15
PL357601A1 (en) 2004-07-26
CN1218943C (zh) 2005-09-14
NZ518828A (en) 2004-03-26

Similar Documents

Publication Publication Date Title
DE122007000064I1 (de) Erythropoietinkonjugate
DE10084676T1 (de) Einmallanzettvorrichtung
DE60001240D1 (de) Laserdepiliergerät
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE59909346D1 (de) Zylinderkopfdichtung
DE50015451D1 (de) Spülwannensystem
DE59910286D1 (de) Kniehebel-spannvorrichtung
DE50007953D1 (de) Beleuchtungsanordung
DE50016100D1 (de) Gabtriebs
DE60000107D1 (de) Formschliessvorrichtung
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE60001471D1 (de) 4-Hydroxyisothiazolverbindungen
DE50003660D1 (de) Diacylhydrazinderivate
DE60000940D1 (de) Wälzlagerstahl
DE59906520D1 (de) Exzenterzahnradgetriebe
DE50006013D1 (de) Anschlagpuffer
DE50003259D1 (de) Textilie
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50008429D1 (de) Kraftstofffraktioniereinrichtung
DE60018859D1 (de) Vorübertragungstonerbehandlung
DE50006759D1 (de) Piperidinalkohole
ATE440824T1 (de) Nitro-sulfobenzamide
DE50006829D1 (de) Benzoylpyridazine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees